Exelixis Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Exelixis Inc. Common Stock trades at $59.93 (market cap $14.62B), while Relay Therapeutics Inc. Common Stock trades at $17.62 (market cap $3.82B). The key difference: Exelixis Inc. Common Stock is far larger — about 3.8× Relay Therapeutics Inc. Common Stock's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Relay Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| EXEL | RLAY | |
|---|---|---|
Market Cap | $14.62B | $3.82B |
Volume | 2,684,957 | 4,332,079 |
Sector | Health | Health |
52-Week High | $59.13 | $20.75 |
52-Week Low | $34.54 | $6.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $13.95B | $2.93B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →